At the news
? BULLISHIMPACT 6/10 8-K filed Jun 30, 2026 at 08:02 ET
Stoke Therapeutics completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, ahead of a Phase 3 data readout anticipated in Q3 2027 and a rolling NDA submission expected to begin in Q1 2027. This de-risks the pivotal trial timeline and sets up a potential U.S. launch by early 2028, though no efficacy or safety data have been released yet.
- Enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen completed across U.S., U.K., and Japan.
- No patients have discontinued treatment in the study.
- Phase 3 data readout anticipated in Q3 2027; rolling NDA submission to FDA to begin Q1 2027 and complete H2 2027.
- Approximately 50 of 162 patients are through 28 weeks (primary endpoint of change in major motor seizure frequency).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access